EU Gives Consortium $1.6M for Ultrasound-triggered Drug Delivery

The EU has awarded about $1.6 million to a consortium of companies developing an ultrasound-triggered drug-delivery technology. With this technology, tumors are hit with a nanosized drug carrier, which is activated by an ultrasound device. The money will be used to push the technology from laboratory to patient.

The consortium is composed of Epitarget of Norway, the French laboratory INSERM and EDAP TMS, a French company that develops therapeutic ultrasound products. The investment will allow the consortium to develop an ultrasound prototype and conduct safety and efficacy studies in